Status:
COMPLETED
Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroi...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- No signs or symptoms of rhinitis outside of the relevant airborne allergen season.
- Exclusion criteria:
- History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments.
- Symptoms of rhinitis at inclusion indicated by total VAS score of \>40 for the combined symptoms scores for blockage, rhinorrhoea, sneezing, itching) or a single symptom with a VAS score \>20.
- Subjects not showing a nasal response to allergen concentration =\< 10,000 BU/ml.
- Subjects with positive skin prick test for Dust House Mite.
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00348361
Start Date
April 1 2005
Last Update
October 13 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
2
GSK Investigational Site
London, London, United Kingdom, WC1X 8DA